Spots Global Cancer Trial Database for drug therapy
Every month we try and update this database with for drug therapy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Effect of Sapanisertib (MLN0128) on the QTc Interval in Participants With Advanced Solid Tumors | NCT02197572 | Advanced Solid ... | Sapanisertib | 18 Years - | Calithera Biosciences, Inc | |
| A Spanish Medical Record Review of Clinical Characteristics and Outcomes in Non-small Cell Lung Cancer Participants With EGFR Exon 20 Insertion | NCT05419700 | Non-small Cell ... | 18 Years - | Takeda | ||
| A Study of TAK-079 in People With Generalized Myasthenia Gravis | NCT04159805 | Myasthenia Grav... | TAK-079 TAK-079 Placebo | 18 Years - | Takeda | |
| A Study to Investigate the Relationship Between Duration of Treatment and Response in Patients With Multiple Myeloma (MM) or Systemic AL Amyloidosis Treated in Real-life Practice | NCT04659798 | Multiple Myelom... Immunoglobulin ... | 18 Years - | Takeda | ||
| Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies | NCT01461538 | Acute Lymphoid ... Acute Myeloid L... Anemia, Refract... Solid Tumors | brentuximab ved... brentuximab ved... brentuximab ved... | 6 Years - | Seagen Inc. | |
| A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma | NCT04837222 | Lymphoma | No Intervention | 18 Years - | Takeda | |
| A Study for Post-Marketing Surveillance of Niraparib in the Treatment of Adult Participants for Approved Indications in South Korea | NCT04589039 | Ovarian Neoplas... | 19 Years - | Takeda | ||
| A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma | NCT05590377 | Multiple Myelom... | Modakafusp Alfa Daratumumab | 18 Years - | Takeda | |
| Antiestrogen vs Aromatase Inhibitor After Adjuvant Chemotherapy for Breast Cancer | NCT00437359 | Breast Neoplasm... | Toremifene citr... Anastrozole | - | Japan Breast Cancer Research Network | |
| A Study of Chinese Adults With Lymphoma | NCT05288491 | Lymphoma | 18 Years - | Takeda | ||
| A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma | NCT01217957 | Multiple Myelom... | Ixazomib Lenalidomide Dexamethasone | 18 Years - | Takeda | |
| Cohort Study of Pioglitazone and Cancer Incidence in Participants With Diabetes Mellitus. | NCT02958956 | Diabetes Mellit... | Pioglitazone | 40 Years - | Takeda | |
| A Study of Brigatinib to Treat Adults With Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non Small Cell Lung Cancer (NSCLC) | NCT04887519 | Carcinoma, Non-... Anaplastic Lymp... | No Intervention | 18 Years - | Takeda | |
| Neoadjuvant FOLFOXIRI Chemotherapy in Resectable Liver Metastasis of Colorectal Cancer | NCT03487939 | Colorectal Neop... Drug Therapy | FOLFOXIRI | 18 Years - 75 Years | China Medical University, China | |
| Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors | NCT02367352 | Advanced Solid ... Ovarian Cancer Small Cell Lung... | Alisertib Paclitaxel | 18 Years - | Takeda | |
| A Study to Check How Often People Treated With Darvadstrocel for Crohn's Disease Are Diagnosed With Cancer | NCT04971525 | Crohn Disease Complex Periana... | 18 Years - | Takeda | ||
| Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data | NCT00341939 | Prostate Cancer Breast Cancer Cutaneous T-Cel... Lung Cancer Melanoma | 18 Years - | National Institutes of Health Clinical Center (CC) | ||
| Effects of Anesthetic Techniques on Time to Start of Adjuvant Chemotherapy Following Surgery for Colorectal Cancer | NCT04493905 | Colorectal Neop... Anesthesia Drug Therapy Surgery | 18 Years - | European Society of Anaesthesiology | ||
| A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers | NCT04879849 | Carcinoma, Non-... Triple Negative... Squamous Cell C... | Pembrolizumab TAK-676 Image-guided ra... | 18 Years - | Takeda | |
| A Trial of Neoadjuvant Chemotherapy + Surgery vs. Surgery for Bulky Stage I/II Cervical Cancer | NCT00190528 | Cervical Neopla... | neoadjuvant che... radical hystere... | 20 Years - 70 Years | Japan Clinical Oncology Group | |
| A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM) | NCT03173092 | Multiple Myelom... | Ixazomib Lenalidomide Dexamethasone | 18 Years - | Takeda | |
| Individualised Versus Standard Care for Breast Cancer Patients at High-risk for Chemotherapy-induced Nausea and Vomiting The ILIAD Study | NCT02861859 | Breast Cancer | Olanzapine Olanzapine Plac... | 18 Years - | Ottawa Hospital Research Institute | |
| Study of Postoperative Concurrent Chemo-radiation With Capecitabine in Elderly Rectal Cancer Patients | NCT01268943 | Rectal Neoplasm... | Capecitabine Capecitabine Capecitabine Capecitabine | 71 Years - | ChineseAMS | |
| A Safety Study of SGN-CD19A for Leukemia and Lymphoma | NCT01786096 | Burkitt Lymphom... Precursor B-cel... | SGN-CD19A | 1 Year - | Seagen Inc. | |
| Potential Therapeutic Response In Urogenital Tumors | NCT03551457 | Urogenital Neop... Drug Therapy | Biopsy | 18 Years - | University of Campinas, Brazil | |
| Helicobacter Pylori Eradication to Prevent Gastric Cancer | NCT01133951 | Helicobacter In... Stomach Neoplas... | OAC triple ther... Placebo | 30 Years - 59 Years | Second Military Medical University | |
| Viral Load Changes in Lymphoma Patients With HCV Infection After Chemotherapy | NCT02588560 | Lymphoma Hepatitis C Ant... Drug Therapy | 20 Years - | Chang Gung Memorial Hospital | ||
| Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer | NCT02412670 | High Grade Uppe... | Methotrexate Vinblastine Doxorubicin Cisplatin Gemcitabine Carboplatin Pegfilgrastim Nephroureterect... | 18 Years - | Eastern Cooperative Oncology Group | |
| A Study to Evaluate Available Treatment Information of Ponatinib, Bosutinib, Imatinib, Dasatinib and Nilotinib in Adults With Chronic Myeloid Leukemia | NCT05743465 | Leukemia | No Intervention | 18 Years - | Takeda | |
| Gemcitabine, Oxaliplatin and Radiation Therapy in Pancreatic Cancer | NCT00242190 | Pancreatic Neop... | oxaliplatin gemcitabine radiation thera... | 18 Years - | University of Michigan Rogel Cancer Center | |
| A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors | NCT03546894 | Anaplastic Lymp... Carcinoma Non-s... | Brigatinib Alectinib Ceritinib Lorlatinib Any FDA Approve... | 18 Years - | Takeda | |
| A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) | NCT01716806 | Hodgkin Disease Peripheral T Ce... | brentuximab ved... bendamustine dacarbazine nivolumab | 18 Years - | Seagen Inc. | |
| Mifamurtide (L-MTP-PE) for High-Risk Osteosarcoma | NCT00631631 | Osteosarcoma | Mifamurtide (L-... | 2 Years - 50 Years | Millennium Pharmaceuticals, Inc. | |
| A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma | NCT01166490 | Gastric Neoplas... Pancreatic Neop... | ASG-5ME | 18 Years - | Seagen Inc. | |
| A Safety Study of SGN-CD19A for B-Cell Lymphoma | NCT01786135 | Burkitt Lymphom... Lymphoma, Folli... Lymphoma, Large... Lymphoma, Mantl... Precursor B-cel... | SGN-CD19A | 12 Years - | Seagen Inc. | |
| A Study to Evaluate TAK-931 in Participants With Advanced Nonhematologic Tumors | NCT02699749 | Nonhematologic ... | TAK-931 | 20 Years - | Takeda | |
| Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors | NCT01204801 | Breast Cancer | Focused Microwa... Chemotherapy (c... | 18 Years - | Medifocus, Inc. | |
| A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma | NCT01166490 | Gastric Neoplas... Pancreatic Neop... | ASG-5ME | 18 Years - | Seagen Inc. | |
| A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant | NCT02181413 | Multiple Myelom... Autologous Stem... | Ixazomib Citrat... Placebo | 18 Years - | Takeda | |
| A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma | NCT01677390 | Renal Cell Carc... | SGN-75 everolimus | 18 Years - | Seagen Inc. | |
| A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors | NCT03261947 | Metastatic Panc... Colorectal Canc... Esophageal Neop... Carcinoma, Non-... | TAK-931 | 18 Years - | Takeda | |
| Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall | NCT03651375 | Sarcoma Fibrosarcoma Leiomyosarcoma Liposarcoma Myosarcoma Histiocytic Sar... Synovial Sarcom... Lymphangiosarco... Malignant Perip... Myxofibrosarcom... Myxoid Liposarc... Undifferentiate... Pleomorphic Lip... Undifferentiate... Dedifferentiate... Pleomorphic Rha... Malignant Trito... | Sequential chem... Hypofractionate... | 18 Years - 100 Years | Maria Sklodowska-Curie National Research Institute of Oncology | |
| A Safety Study of SGN-LIV1A in Breast Cancer Patients | NCT01969643 | HER2 Positive B... Hormone Recepto... Triple Negative... HER2 Mutations ... | ladiratuzumab v... Trastuzumab | 18 Years - | Seagen Inc. | |
| A Safety, Tolerability, and Pharmacokinetics Study of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies | NCT02412722 | Non-hematologic... | Sapanisertib Paclitaxel | 18 Years - | Takeda | |
| CASIMAS: Catumaxomab Safety Phase IIIb Study With Intraperitoneal Infusion in Patients With Malignant Ascites Due to Epithelial Cancers | NCT00822809 | Cancer Neoplasms Carcinoma Malignant Ascit... | Catumaxomab Prednisolone | 18 Years - | Neovii Biotech | |
| A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma | NCT02954406 | Lymphoma, Non-H... | TAK-659 Bendamustine Rituximab Gemcitabine Lenalidomide Ibrutinib | 18 Years - | Takeda | |
| A Study of People With CD30 Positive Lymphoma in China | NCT05506774 | Lymphoma | 18 Years - | Takeda | ||
| Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy | NCT02756364 | Breast Neoplasm... | Fulvestrant Sapanisertib | 18 Years - | Calithera Biosciences, Inc | |
| A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma | NCT01564537 | Relapsed Multip... Refractory Mult... | Ixazomib Lenalidomide Dexamethasone Placebo | 18 Years - | Takeda | |
| A Phase 1 Study of IXAZOMIB in Adult Patients With Advanced Nonhematologic Malignancies | NCT00830869 | Advanced Non-he... | IXAZOMIB | 18 Years - | Takeda | |
| A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes | NCT04985656 | Myelodysplastic... | Pevonedistat Decitabine Cedazuridine | 18 Years - | Takeda | |
| A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib | NCT02094573 | Carcinoma, Non-... | Brigatinib | 18 Years - | Takeda | |
| A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer | NCT02716116 | Carcinoma, Non-... | TAK-788 | 18 Years - | Takeda | |
| A Study of Ninlaro in Real World Clinical Practice in China | NCT04328662 | Multiple Myelom... Neoplasms, Plas... | 18 Years - | Takeda | ||
| A Safety and Tolerability Study of Peginesatide in Anemic Cancer Patients Receiving Cytotoxic Chemotherapy. | NCT00629876 | Anemia | Peginesatide | 18 Years - 80 Years | Takeda | |
| A Safety, Tolerability, and Pharmacokinetics Study of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies | NCT02412722 | Non-hematologic... | Sapanisertib Paclitaxel | 18 Years - | Takeda | |
| Study of Postoperative Concurrent Chemo-radiation With Capecitabine in Elderly Rectal Cancer Patients | NCT01268943 | Rectal Neoplasm... | Capecitabine Capecitabine Capecitabine Capecitabine | 71 Years - | ChineseAMS | |
| Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) | NCT01026415 | Carcinomas Disease, Hodgki... Lymphoma, Large... Lymphoma, Non-H... Neoplasms | brentuximab ved... rifampin midazolam ketoconazole brentuximab ved... | 18 Years - | Seagen Inc. | |
| A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT) | NCT02312258 | Multiple Myelom... | Placebo Ixazomib | 18 Years - | Takeda | |
| Study to See How Safe Curcumin is and How Well it Works When Used to Treat Mucositis in Patients Getting Chemotherapy | NCT02300727 | Mucositis | Curcumin-MTD Mouthwash-stand... Curcumin | 18 Years - | Aurora BayCare Medical Center | |
| A Phase 2 Trial of MLN8237 in Adult Participants With Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome | NCT00830518 | Acute Myelogeno... High-Grade Myel... | Alisertib | 18 Years - | Takeda | |
| A Safety Study of SGN-CD19A for B-Cell Lymphoma | NCT01786135 | Burkitt Lymphom... Lymphoma, Folli... Lymphoma, Large... Lymphoma, Mantl... Precursor B-cel... | SGN-CD19A | 12 Years - | Seagen Inc. | |
| A Safety, Tolerability, and Pharmacokinetics Study of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies | NCT02412722 | Non-hematologic... | Sapanisertib Paclitaxel | 18 Years - | Takeda | |
| A Safety Study of SGN-CD123A in Patients With Acute Myeloid Leukemia | NCT02848248 | Acute Myeloid L... | SGN-CD123A | 18 Years - 74 Years | Seagen Inc. | |
| A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors | NCT04420884 | Solid Neoplasms | Dazostinag Pembrolizumab Platinum 5-fluorouracil | 18 Years - | Takeda | |
| A Study to Evaluate TAK-931 in Participants With Advanced Nonhematologic Tumors | NCT02699749 | Nonhematologic ... | TAK-931 | 20 Years - | Takeda | |
| A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors | NCT02045095 | Advanced Malign... | MLN7243 | 18 Years - | Takeda | |
| A Study of Real-World Use of Ixazomib Citrate in People With Multiple Myeloma (MM) | NCT04840680 | Multiple Myelom... | No Intervention | - | Takeda | |
| Livestrong Cancer Institutes' Patient Reported Outcomes Study | NCT04627077 | Neoplasms Drug Therapy | 18 Years - | University of Texas at Austin | ||
| A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL) | NCT05673785 | Lymphoma | Brentuximab Ved... Cyclophosphamid... Doxorubicin Prednisone | 18 Years - | Takeda | |
| A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors | NCT03546894 | Anaplastic Lymp... Carcinoma Non-s... | Brigatinib Alectinib Ceritinib Lorlatinib Any FDA Approve... | 18 Years - | Takeda | |
| A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors | NCT02045095 | Advanced Malign... | MLN7243 | 18 Years - | Takeda | |
| A Safety and Pharmacokinetic Study of TAK-228 in Combination With TAK-117 in Adult Participants With Advanced Nonhematologic Malignancies | NCT01899053 | Advanced Nonhem... | TAK-228 TAK-117 | 18 Years - | Takeda | |
| A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma | NCT04837222 | Lymphoma | No Intervention | 18 Years - | Takeda | |
| A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib | NCT03535740 | ALK-positive Ad... | Brigatinib | 18 Years - | Takeda | |
| Study of Motesanib (AMG 706) in Combination With Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer | NCT02629848 | Carcinoma, Non-... | Motesanib Placebo Paclitaxel Carboplatin | 18 Years - | Takeda | |
| A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial) | NCT01100502 | Disease, Hodgki... | brentuximab ved... placebo | 18 Years - | Seagen Inc. | |
| Characterisation and Epidemiology of Breakthrough Cancer Pain in Spain | NCT02899884 | Breakthrough Ca... | No Intervention | 18 Years - | Takeda | |
| Effect of Dexlansoprazole 60 mg QD and 60 mg BID on Recurrence of Intestinal Metaplasia in Subjects Who Have Achieved Complete Eradication of Barrett's Esophagus With Radiofrequency Ablation | NCT02162758 | Barrett's Esoph... | Dexlansoprazole Dexlansoprazole... | 18 Years - 80 Years | Takeda | |
| Gene Expression Profiling of Metastatic Breast Cancer Predict the Therapeutic Response to Chemotherapy | NCT01198301 | Breast Neoplasm... Neoplasm Metast... | 18 Years - 75 Years | Peking University Cancer Hospital & Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
